Inhibitory effect of dihydromyricetin on the proliferation of JAR cells and its mechanism of action

Zuo,Yanzhen; Lu,Yanjie; Xu,Qian; Sun,Dayong; Liang,Xiujun; Li,Xiaoru; Li,Yuhong

doi:10.3892/ol.2020.11546

Inhibitory effect of dihydromyricetin on the proliferation of JAR cells and its mechanism of action

Authors:
- Yanzhen Zuo
- Yanjie Lu
- Qian Xu
- Dayong Sun
- Xiujun Liang
- Xiaoru Li
- Yuhong Li
View Affiliations

Affiliations: Department of Pharmacology, Chengde Medical University, Chengde, Hebei 067000, P.R. China, Department of Pathology, Chengde Medical University, Chengde, Hebei 067000, P.R. China, Research Laboratory, Chengde Medical University, Chengde, Hebei 067000, P.R. China, Department of Tumor Radiation and Chemotherapy Center, Chengde Central Hospital, Chengde, Hebei 067000, P.R. China, Department of Gynaecology, Chengde Central Hospital, Chengde, Hebei 067000, P.R. China
Published online on: April 16, 2020 https://doi.org/10.3892/ol.2020.11546
Pages: 357-363
Copyright: © Zuo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dihydromyricetin (DMY) is a novel natural drug with antitumor activity against some cancer cells without obvious toxicity. Previously, its apoptotic effect on human choriocarcinoma was detected. The present study further investigated the therapeutic potential of DMY as a new drug for the treatment of choriocarcinoma, as well as its anti‑proliferative effect and mechanism of action. The short‑term proliferation of JAR cells was determined by MTT assay, whereas the effect of DMY on long‑term cell proliferation was determined by colony forming assay. Flow cytometry was used to detect changes in the cell cycle. Furthermore, western blotting was used to detect the expression levels of proliferation‑associated proteins such as cyclin A1, cyclin D1, SMAD3 and SMAD4. Reverse transcription‑quantitative PCR (RT‑qPCR) was used to quantify mRNA expression levels. The results indicated that DMY inhibited short and long‑term proliferation of JAR cells in a concentration‑dependent manner. Flow cytometry demonstrated S/G2/M cell cycle arrest, and western blotting revealed the downregulation of SMAD3, SMAD4, cyclin A1 and cyclin D1 expression levels. The results of RT‑qPCR and western blotting were consistent. Overall, the findings of the present study suggest that DMY inhibits the proliferation of human choriocarcinoma JAR cells, potentially through cell cycle arrest via the downregulation of cyclin A1, cyclin D1, SMAD3 and SMAD4 expression levels.

View Figures

View References

1	Pires LV, Yi Y, Cheng JC, Pizzolato LS, Cordero E, Leung PCK and Brum IS: Lapatinib inhibits amphiregulin-induced BeWo choriocarcinoma cell proliferation by reducing ERK1/2 and AKT signaling pathways. Anticancer Res. 39:2377–2383. 2019. View Article : Google Scholar : PubMed/NCBI
2	Yu S, Wu C, Tan Q and Liu H: Long noncoding RNA H19 promotes chemotherapy resistance in choriocarcinoma cells. J Cell Biochem. 120:15131–15144. 2019. View Article : Google Scholar : PubMed/NCBI
3	Pearce H, Edwards DC, Levy JA, McGreen BH, Mackovick L, Brennan M, McHugh M, Mapow B, Schanne FJ and Belkoff L: Acute pulmonary hemorrhage associated with metastatic testicular choriocarcinoma in a 46-year-old incarcerated male. Urol Ann. 11:109–112. 2019. View Article : Google Scholar : PubMed/NCBI
4	Breitbach GP, Sklavounos P, Veith C, Costa SD, Kuhn W, Solomayer EF, Juhasz-Boess I and Tempfer C: Oral etoposide for metastatic choriocarcinoma: A case report and review of guidelines. Arch Gynecol Obstet. 299:1115–1119. 2019. View Article : Google Scholar : PubMed/NCBI
5	Wu C, Yu S, Tan Q, Guo P and Liu H: Role of AhR in regulating cancer stem cell-like characteristics in choriocarcinoma. Cell Cycle. 17:2309–2320. 2018. View Article : Google Scholar : PubMed/NCBI
6	Li H, Li Q, Liu Z, Yang K, Chen Z, Cheng Q and Wu L: The versatile effects of dihydromyricetin in health. Evid Based Complement Alternat Med. 2017:10536172017. View Article : Google Scholar : PubMed/NCBI
7	Jiang L, Zhang Q, Ren H, Ma S, Lu C, Liu B, Liu J, Liang J, Li M and Zhu R: Dihydromyricetin enhances the chemo-sensitivity of nedaplatin via regulation of the p53/Bcl-2 pathway in hepatocellular carcinoma cells. PLoS One. 10:e01249942015. View Article : Google Scholar : PubMed/NCBI
8	Wong IL, Wang BC, Yuan J, Duan LX, Liu Z, Liu T, Li XM, Hu X, Zhang XY, Jiang T, et al: Potent and nontoxic chemosensitizer of P-glycoprotein-mediated multidrug resistance in cancer: Synthesis and evaluation of methylated epigallocatechin, gallocatechin, and dihydromyricetin derivatives. J Med Chem. 58:4529–4549. 2015. View Article : Google Scholar : PubMed/NCBI
9	Kao SJ, Lee WJ, Chang JH, Chow JM, Chung CL, Hung WY and Chien MH: Suppression of reactive oxygen species-mediated ERK and JNK activation sensitizes dihydromyricetin-induced mitochondrial apoptosis in human non-small cell lung cancer. Environ Toxicol. 32:1426–1438. 2017. View Article : Google Scholar : PubMed/NCBI
10	Zhou DZ, Sun HY, Yue JQ, Peng Y, Chen YM and Zhong ZJ: Dihydromyricetin induces apoptosis and cytoprotective autophagy through ROS-NF-κB signalling in human melanoma cells. Free Radic Res. 51:517–528. 2017. View Article : Google Scholar : PubMed/NCBI
11	Huang X, Lian T, Guan X, Liu B, Hao S, Zhang J, Bao S, Tan X and Zhu R: Dihydromyricetin reduces TGF-β via P53 activation-dependent mechanism in hepatocellular carcinoma HepG2 cells. Protein Pept Lett. 24:419–424. 2017. View Article : Google Scholar : PubMed/NCBI
12	Zhang QY, Li R, Zeng GF, Liu B, Liu J, Shu Y, Liu ZK, Qiu ZD, Wang DJ, Miao HL, et al: Dihydromyricetin inhibits migration and invasion of hepatoma cells through regulation of MMP-9 expression. World J Gastroenterol. 20:10082–10093. 2014. View Article : Google Scholar : PubMed/NCBI
13	Zuo Y, Xu Q, Lu Y, Sun D, Wang K, Lei Y, Liang X and Li Y: Dihydromyricetin induces apoptosis in a human choriocarcinoma cell line. Oncol Lett. 16:4229–4234. 2018.PubMed/NCBI
14	Alberts B, Bray D, Hopkin K, Johnson A, Lewis J, Raff M, Roberts K and Walter P: Essential cell biology. (Fourth). Garland Science. Taylor & Francis Group, LLC. (USA). 2014.
15	Li Y, Xu Q, Zhang Z, Liu S, Shi C and Tan Y: The impact of TGF-β1 on the mRNA expression of TβR I, TβR II, Smad4 and the invasiveness of the JEG-3 placental choriocarcinoma cell line. Oncol Lett. 4:1344–1348. 2012. View Article : Google Scholar : PubMed/NCBI
16	Tan Y, Xu Q, Li Y, Mao X and Zhang K: Crosstalk between the p38 and TGF-β signaling pathways through TβRI, TβRII and Smad3 expression in plancental choriocarcinoma JEG-3 cells. Oncol Lett. 8:1307–1311. 2014. View Article : Google Scholar : PubMed/NCBI
17	Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R and Mathieu C: An overview of real-time quantitative PCR: Applications to quantify cytokine gene expression. Methods. 25:386–401. 2001. View Article : Google Scholar : PubMed/NCBI
18	Evans T, Rosenthal ET, Youngblom J, Distel D and Hunt T: Cyclin: A protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell. 33:389–396. 1983. View Article : Google Scholar : PubMed/NCBI
19	Fung TK and Poon RY: A roller coaster ride with the mitotic cyclins. Semin Cell Dev Biol. 16:335–342. 2005. View Article : Google Scholar : PubMed/NCBI
20	Motokura T, Bloom T, Kim HG, Jüppner H, Ruderman JV, Kronenberg HM and Arnold A: A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 350:512–515. 1991. View Article : Google Scholar : PubMed/NCBI
21	Masclef L, Dehennaut V, Mortuaire M, Schulz C, Leturcq M, Lefebvre T and Vercoutter-Edouart AS: Cyclin D1 stability is partly controlled by O-GlcNAcylation. Front Endocrinol (Lausanne). 10:1062019. View Article : Google Scholar : PubMed/NCBI
22	Yan KX, Liu BC, Shi XL, You BR and Xu M: Role of cyclinD1 and CDK4 in the carcinogenesis induced by silica. Biomed Environ Sci. 18:286–296. 2005.PubMed/NCBI
23	Hsu CC, Chen CH, Hsu TI, Hung JJ, Ko JL, Zhang B, Lee YC, Chen HK, Chang WC and Lin DY: The 58-kda microspherule protein (MSP58) represses human telomerase reverse transcriptase (hTERT) gene expression and cell proliferation by interacting with telomerase transcriptional element-interacting factor (TEIF). Biochim Biophys Acta. 1843:565–579. 2014. View Article : Google Scholar : PubMed/NCBI
24	Kang X, Wang H, Li Y, Xiao Y, Zhao L, Zhang T, Zhou S, Zhou X, Li Y, Shou Z, et al: Alantolactone induces apoptosis through ROS-mediated AKT pathway and inhibition of PINK1-mediated mitophagy in human HepG2 cells. Artif Cells Nanomed Biotechnol. 47:1961–1970. 2019. View Article : Google Scholar : PubMed/NCBI
25	Wu Z, Wang C, Huang M, Tao Z, Yan W and Du Y: Naturally occurring sesquiterpene lactone-santonin, exerts anticancer effects in multi-drug resistant breast cancer cells by inducing mitochondrial mediated apoptosis, caspase activation, cell cycle arrest, and by targeting Ras/Raf/MEK/ERK signaling pathway. Med Sci Monit. 25:3676–3682. 2019. View Article : Google Scholar : PubMed/NCBI
26	Si L, Jia Y, Lin R, Jian W, Yu Q and Yang S: MicroRNA-27a regulates the proliferation, chemosensitivity and invasion of human ovarian cancer cell lines by targeting Cullin 5. Arch Biochem Biophys. 668:9–15. 2019. View Article : Google Scholar : PubMed/NCBI
27	Mao Z, Shen X, Dong P, Liu G, Pan S, Sun X, Hu H, Pan L and Huang J: Fucosterol exerts antiproliferative effects on human lung cancer cells by inducing apoptosis, cell cycle arrest and targeting of Raf/MEK/ERK signalling pathway. Phytomedicine. 61:1528092019. View Article : Google Scholar : PubMed/NCBI
28	Sun W, Guo F and Liu M: Up-regulated WDR5 promotes gastric cancer formation by induced cyclin D1 expression. J Cell Biochem. 119:3304–3316. 2018. View Article : Google Scholar : PubMed/NCBI
29	Zhou J, Zhang C, Zhou B and Jiang D: miR-183 modulated cell proliferation and apoptosis in ovarian cancer through the TGF-β/Smad4 signaling pathway. Int J Mol Med. 43:1734–1746. 2019.PubMed/NCBI
30	Sun L, Dong Z, Gu H, Guo Z and Yu Z: TINAGL1 promotes hepatocellular carcinogenesis through the activation of TGF-β signaling-medicated VEGF expression. Cancer Manag Res. 11:767–775. 2019. View Article : Google Scholar : PubMed/NCBI
31	Shi Y and Massagué J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 113:685–700. 2003. View Article : Google Scholar : PubMed/NCBI
32	Zuo Y, Fu Z, Hu Y, Li Y, Xu Q, Sun D and Tan Y: Effects of transforming growth factor-β1 on the proliferation and invasion of the HTR-8/SVneo cell line. Oncol Lett. 8:2187–2192. 2014. View Article : Google Scholar : PubMed/NCBI
33	Li Q, Liu X and Zhao C: Smad4 gene silencing enhances the chemosensitivity of human lymphoma cells to adriamycin via inhibition of the activation of transforming growth factor β signaling pathway. J Cell Biochem. 120:15098–15105. 2019. View Article : Google Scholar : PubMed/NCBI